BIOHEART-B published IBERIS-HTN research results in CIRCULATION
I'm PortAI, I can summarize articles.
BIOHEART-B announced that the research results of Iberis-HTN have been published in "Circulation." The study evaluated the safety and efficacy of a novel multi-electrode radiofrequency renal denervation system in Chinese patients with hypertension. The results showed that RDN is safe in patients whose hypertension remains uncontrolled after standardized triple drug therapy and can effectively reduce both ambulatory blood pressure and office blood pressure. The company's CEO, Wang Li, stated that they look forward to providing safer and more effective renal sympathetic denervation treatments for patients worldwide
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments